ILA's Principal Activity is the drug research and repurposing
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-57.31%|
Island Pharmaceuticals Limited (ILA) is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its lead product candidate is Isla101 for the treatment and/or prevention of mosquito borne viruses, such as dengue fever.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Dr David Lionel Brookes||Non-Executive Director||Oct 2020||
Dr David Lionel Brookes
Dr Brookes has experience in the health and biotechnology industries and has held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI ) in June 2018. He is currently the non-executive Chairman of ASX listed Factor Therapeutics Ltd and of Anatara Lifesciences Ltd . He is currently a non-executive director of ASX listed company TALi Digital Ltd and is the chair of the Audit & Risk committee
|Dr David Foster||Managing Director||Oct 2020||
Dr David Foster
Dr Foster has vast experience in the life science industry including 20+ years representing diverse companies, such as pharmaceutical, biotherapeutic and diagnostic companies while in private legal practice. In addition, he served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb. Dr Foster co-founded Roberts Foster LLP- a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies. He is a Board member of bionorthTx and private biotechnology companies. Dr Foster has expertise in formulating intellectual property and business strategies to protect and develop therapeutic assets.
|Mr Albert Hansen||Non-Executive Director||Oct 2020||
Mr Albert Hansen
Mr Hansen is currently President of KESA Partners, Inc. (KESA) a family investment office focused on seed investing in life science-related startups. KESA provides capital and strategic management to its portfolio companies. Mr. Hansen serves as President of one of KESA's portfolio companies, Clearlight Biotechnologies, Inc., which has licensed imaging technology for tissue analysis from Stanford University. From 2001 to 2012, Mr. Hansen was a Managing Director of Signet Healthcare Partners, a growth capital private equity firm focused on emerging life science companies. Mr. Hansen has over 25 years of private equity investment experience, with almost 20 years in the life sciences/pharmaceutical field. He is a former Chairman and interim CEO of Questcor Pharmaceuticals, Inc (later acquired for US$5 billion), a former Chairman and interim CEO of Cedarburg Pharmaceuticals Inc. (acquired for US$40 million) and former Chairman of Molecular Medicine Corporation (acquired for US$24 million). KESA Partners, Inc acquired a failing company, Bioserv Corporation, for US$25,000 from NextPharma, Ltd in November 2012. He has also been a director of over ten other private companies. Prior to Signet, Mr Hansen was a principal of Darby Overseas, since acquired by Franklin Templeton. He was also a political appointee as Director of Corporate Finance at the U.S. Treasury Department in 1992. Earlier in his career, Mr Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. He was also an investment banker at E.F. Hutton & Co. Mr Hansen also served in the U.S. Army as an Infantry and Special Forces office
|Dr Anna Lavelle||Non-Executive Director||Oct 2020||
Dr Anna Lavelle
Dr Lavelle is an experienced Non-Executive Director serving for over 25 years on the boards of not for profit, government and for profit entities. As Executive Director or Non-Executive Director she has a lengthy track record in healthcare delivery, technology development and negotiating government policy. In 2015 Nature Scientific America, World View ranked Dr Lavelle in the global top 100 "World Visionaries" in biotechnology. Dr Lavelle was the only Australian to be named. From 2005 to 2016, Dr Lavelle was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors. Dr Lavelle is now serving on several boards including - Independent Chair, Medicines Australia Ltd, Independent Chair, Avatar Brokers Pty Ltd, Non- Executive Director Hemideina Pty Ltd, NonExecutive Director Cyban Pty Ltd
|Dr Paul MacLeman||Executive Chairman,Executive Director||May 2020||
Dr Paul MacLeman
Executive Chairman,Executive Director
Dr MacLeman has over 25 years' experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Dr MacLeman has expertise in capital raising, business development, technology commercialisation and sales & marketing globally. Dr MacLeman has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Dr MacLeman has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Dr MacLeman is currently Chairman of AdAlta Limited (1AD:ASX), Chairman of SuperTrans Medical Limited and nonexecutive director of Upkara Inc. & Upkara Asia Pacific Pty Ltd. Dr MacLeman Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Dr MacLeman also serves on a number of other NFP and government advisory groups.
|Mr Peter Webse||Company Secretary||N/A|
ILA directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|18/11/21||David Brookes||Issued||100,000||$0.25||$25,000||Director remuneration|
|18/11/21||Albert Hansen||Issued||100,000||$0.25||$25,000||Director remuneration|
|18/11/21||Anna Lavelle||Issued||100,000||$0.25||$25,000||Director remuneration|
The current holdings of ILA directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|KESA PARTNERS INC||13/08/2021||10,837,367||13.38|
|David Charles Foster||13/08/2021||5,146,829||6.63|
|William James Garner||19/08/2021||21,913,098||27.06|
|Jason Alan Carroll||28/04/2022||9,900,000||12.18|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|28-04-22||Jason Alan Carroll||814,391||11.17||12.18|
|29-03-22||Jason Alan Carroll||835,609||10.15||11.17|
|01-02-22||Jason Alan Carroll||950,000||9.00||10.15|
|25-11-21||Jason Alan Carroll||1,625,000||7.00||9.00|
|19-10-21||Jason Alan Carroll||800,000||6.00||7.00|
|13-10-21||Jason Alan Carroll||825,000||5.00||6.00|
|19-08-21||William James Garner||822,493||26.05||27.06|
|11-08-21||Jason Alan Carroll||4,050,000||--||5.00|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.